Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Blood cancers, Chronic leukaemia, Chronic lymphocytic leukaemia (CLL), Leukaemia, Lymphoma
Closed
Phase 2
This trial is looking at zilovertamab vedotin by itself or in combination with nemtabrutinib for people with B cell lymphomas and B cell leukaemia.
B cell lymphoma and B cell leukaemia are also called B cells cancers.
It is open to people with one of the following B cell cancers that has come back or got worse during treatment:
Richter transformation. This is also called Richter’s syndrome.
You pronounce zilovertamab vedotin as zi-lov-er-ta-mab veh-doh-tin.
You pronounce nemtabrutinib as nem-tab-rut-i-nib.
Recruitment start: 31 July 2023
Recruitment end: 23 February 2026
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Satyen Gohil
Merck Sharp & Dohme LLC
Last reviewed: 23 Feb 2026
CRUK internal database number: 19601
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
